secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-07-07T21:05:03+00:00
Accession:  0001689548-26-000072
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Precision Medicines partners with Remagine Labs for transdermal patch of ulixacaltamide
--------------------------------------------------------------------------------

- Collaboration to develop iontophoretic transdermal patch for ulixacaltamide for essential tremor.
- Remagine's platform enables precise, multi-day active transdermal dosing.
- Praxis made an equity investment in Remagine to support program advancement.
- Transdermal option intended to broaden patient population and strengthen competitive positioning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000072/0001689548-26-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000072/prax-20260707.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer